The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2018 | Telomere length as a prognostic parameter in CLL
Telomere erosion and fusion play an important role in the pathology of many common human malignancies, including chronic lymphocytic leukemia (CLL). In this interview, Chris Fegan, MB, MD, FRCP, FRCPath, from Cardiff University, Cardiff, UK, discusses the findings of a study analyzed the telomere profiles of CLL patients, to give a better idea of the replicative history of the disease. The study identified the shortest telomeres ever recorded in primary human tissue, reinforcing the concept that there is significant cell division in CLL. The study also provided evidence that critical telomere shortening, dysfunction and fusion contribute to disease progression. This interview was recorded at the British Society for Hematology (BSH) 2018 Annual Scientific Meeting, Liverpool, UK.
